LINCOLN PHARMACEUTICALS
Quarterly Results Analysis [Mar2025]
LINCOLN PHARMACEUTICALS Quarterly Results
Consolidated | Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹168 Cr | ₹147 Cr | ₹161 Cr | ₹147 Cr | ₹142 Cr | ₹146 Cr | ₹156 Cr | ₹136 Cr |
Expenses | ₹141 Cr | ₹123 Cr | ₹133 Cr | ₹125 Cr | ₹124 Cr | ₹117 Cr | ₹125 Cr | ₹115 Cr |
Operating Income | ₹27 Cr | ₹24 Cr | ₹28 Cr | ₹23 Cr | ₹18 Cr | ₹30 Cr | ₹31 Cr | ₹21 Cr |
Other Income | ₹-7 Cr | ₹9 Cr | ₹10 Cr | ₹10 Cr | ₹7 Cr | ₹11 Cr | ₹9 Cr | ₹8 Cr |
Interest | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
Profit Before Tax | ₹16 Cr | ₹29 Cr | ₹35 Cr | ₹29 Cr | ₹22 Cr | ₹38 Cr | ₹37 Cr | ₹25 Cr |
Profit After Tax | ₹12 Cr | ₹21 Cr | ₹26 Cr | ₹24 Cr | ₹19 Cr | ₹28 Cr | ₹28 Cr | ₹19 Cr |
EPS | ₹5.78 | ₹10.37 | ₹13.15 | ₹11.82 | ₹9.28 | ₹14.00 | ₹13.81 | ₹9.49 |
Industry Peers & Returns | 1W | 1M | 1Y |
LINCOLN PHARMACEUTICALS | -3% | -4.4% | -4.9% |
SUN PHARMACEUTICAL INDUSTRIES | 0.2% | -8.3% | 15.9% |
DIVIS LABORATORIES | -1.9% | 8.6% | 55.9% |
CIPLA | -1.3% | -5.5% | -0.1% |
TORRENT PHARMACEUTICALS | -0.5% | -4.2% | 19.3% |
DR REDDYS LABORATORIES | 0.7% | 5.8% | 6.1% |
MANKIND PHARMA | 1.8% | 0.4% | 16.6% |
ZYDUS LIFESCIENCES | 1.9% | 4.8% | -12.7% |
LUPIN | -1.5% | -6.5% | 21.9% |
LINCOLN PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 14.76 % |
Y-o-Y | 18.03 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹168 Cr | 14.76 | |
Dec2024 | ₹147 Cr | -9.09 | |
Sep2024 | ₹161 Cr | 9.46 | |
Jun2024 | ₹147 Cr | 3.36 | |
Mar2024 | ₹142 Cr | -2.70 | |
Dec2023 | ₹146 Cr | -6.12 | |
Sep2023 | ₹156 Cr | 15.02 | |
Jun2023 | ₹136 Cr | - |
LINCOLN PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 12.91 % |
Y-o-Y | 45.35 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹27 Cr | 12.91 | |
Dec2024 | ₹24 Cr | -16.62 | |
Sep2024 | ₹28 Cr | 24.85 | |
Jun2024 | ₹23 Cr | 23.66 | |
Mar2024 | ₹18 Cr | -38.02 | |
Dec2023 | ₹30 Cr | -4.78 | |
Sep2023 | ₹31 Cr | 50.34 | |
Jun2023 | ₹21 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -1.61 % |
Y-o-Y | 23.18 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 15.89% | -1.61 | |
Dec2024 | 16.15% | -8.24 | |
Sep2024 | 17.6% | 14.06 | |
Jun2024 | 15.43% | 19.61 | |
Mar2024 | 12.9% | -36.30 | |
Dec2023 | 20.25% | 1.40 | |
Sep2023 | 19.97% | 30.69 | |
Jun2023 | 15.28% | - |
LINCOLN PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -44.28 % |
Y-o-Y | -37.76 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹12 Cr | -44.28 | |
Dec2024 | ₹21 Cr | -21.12 | |
Sep2024 | ₹26 Cr | 11.23 | |
Jun2024 | ₹24 Cr | 27.29 | |
Mar2024 | ₹19 Cr | -33.67 | |
Dec2023 | ₹28 Cr | 1.39 | |
Sep2023 | ₹28 Cr | 45.44 | |
Jun2023 | ₹19 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -51.45 % |
Y-o-Y | -47.28 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 6.88 % | -51.45 | |
Dec2024 | 14.17 % | -13.23 | |
Sep2024 | 16.33 % | 1.62 | |
Jun2024 | 16.07 % | 23.14 | |
Mar2024 | 13.05 % | -31.85 | |
Dec2023 | 19.15 % | 8.01 | |
Sep2023 | 17.73 % | 26.46 | |
Jun2023 | 14.02 % | - |
LINCOLN PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -44.26 % |
Y-o-Y | -37.72 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹5.78 | -44.26 | |
Dec2024 | ₹10.37 | -21.14 | |
Sep2024 | ₹13.15 | 11.25 | |
Jun2024 | ₹11.82 | 27.37 | |
Mar2024 | ₹9.28 | -33.71 | |
Dec2023 | ₹14 | 1.38 | |
Sep2023 | ₹13.81 | 45.52 | |
Jun2023 | ₹9.49 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD